Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

D Tural, S Serdengecti, F Demirelli, T Öztürk, S İlvan, H Turna, M Özgüroglu, E Büyükünal

Open source

DOI
10.1038/bjc.2014.72
Published
2014-03-04
Container
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/bjc.2014.72,
  title = {Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies},
  author = {D Tural and S Serdengecti and F Demirelli and T Öztürk and S İlvan and H Turna and M Özgüroglu and E Büyükünal},
  year = {2014},
  journal = {British Journal of Cancer},
  doi = {10.1038/bjc.2014.72},
  url = {https://doi.org/10.1038/bjc.2014.72}
}

RIS

TY  - JOUR
TI  - Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
AU  - D Tural
AU  - S Serdengecti
AU  - F Demirelli
AU  - T Öztürk
AU  - S İlvan
AU  - H Turna
AU  - M Özgüroglu
AU  - E Büyükünal
PY  - 2014
JO  - British Journal of Cancer
DO  - 10.1038/bjc.2014.72
UR  - https://doi.org/10.1038/bjc.2014.72
ER  - 

APA

Tural, D., Serdengecti, S., Demirelli, F., Öztürk, T., İlvan, S., Turna, H., Özgüroglu, M., & Büyükünal, E. (2014). Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. British Journal of Cancer. https://doi.org/10.1038/bjc.2014.72

Source records